<DOC>
	<DOCNO>NCT00724841</DOCNO>
	<brief_summary>Obatoclax Mesylate ( GMX1777 ) water-soluble , intravenously-administered pro-drug GMX1778 . GMX1777 rapidly convert GMX1778 vivo . GMX1778 potent anti-tumor activity variety cell line model different tumor origin .</brief_summary>
	<brief_title>A Phase I/II Study GMX1777 Combination With Temozolomide Treatment Metastatic Melanoma</brief_title>
	<detailed_description>GMX1777 administer 3-Hour Infusions Combination Temozolomide take orally treatment Metastatic Melanoma . GMX1777 infusion give either day 1 , day 1 3 , day 1,3 , 5 every 4 week . Temozolomide administer 5 consecutive day every 4 week . No investigational commercial agent therapy describe may administer intent treat patient 's malignancy .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Histologically cytologically confirm metastatic melanoma Up 1 prior chemotherapy regimen allow ; prior immunotherapy allow Normal organ marrow function Willing submit blood sampling plan PK/PD analyse Ability understand willingness sign write informed consent No investigational commercial agent therapy Prior exposure GMX1777 , GMX1778 CHS828 Patients uncontrolled , intercurrent illness Pregnant breastfeeding woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>